Zealand Pharma announced positive Phase III trial results from Boehringer Ingelheim's survodutide, a glucagon/GLP-1 dual agonist, showing up to 34% visceral fat and 63% liver fat reduction in people with obesity, alongside up to 16.6% weight loss over 76 weeks. The SYNCHRONIZE-1 and SYNCHRONIZE-MASLD trials demonstrated that survodutide not only reduces weight but also targets metabolically harmful fat and improves liver health in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). These results, presented at the American Diabetes Association 2026 Scientific Sessions and published in leading medical journals, highlight survodutide's potential as a novel treatment for obesity and related metabolic conditions. Zealand Pharma is eligible for royalties and milestone payments as Boehringer Ingelheim advances further Phase IIIb studies to optimize patient care and dosing.
BeautyPlus, an AI-powered photo editing app by Pixocial, introduced the AI Tattoo Generator, allowing users to virtually try on realistic tattoo designs using their own photos. This feature helps users visualize different tattoo styles, placements, a...
rEvolution has been appointed by Hurricane Group as the agency of record for FISE Birmingham 2026, the only U.S. stop of the global FISE World Series action sports festival. The agency, alongside its digital group WePlay, will handle digital ticketin...
American Airlines Group will hold its virtual annual meeting of stockholders on June 10, 2026, at 9 a.m. CT. The meeting will be accessible to all interested parties through online registration, allowing stockholders to submit questions in writing du...
HERE, a lifestyle IP brand, has launched the fourth-generation WAKUKU series called The Handicraft World of WAKUKU, featuring vinyl plush blind boxes inspired by handcrafted aesthetics and themes of repair and emotional healing. This new collection i...
ZenaTech, a tech company specializing in AI-powered drones and related services, has been added to the Russell 3000 index effective June 29, 2026. This inclusion marks a significant milestone reflecting the company's growth and increased market capit...
